www.oncnursingnews.com Open in urlscan Pro
76.76.21.98  Public Scan

Submitted URL: https://email.productiveedge.com/e3t/Ctc/2K+113/cCGDd04/VVHbF21cS-7ZN4qckHGzTQyfW56dvtZ5b7q9HN7Cq3w05nR32W50kH_H6lZ3pbN8KZz6by_JS...
Effective URL: https://www.oncnursingnews.com/view/prior-authorization-is-top-administrative-challenge-of-2023?utm_campaign=Health%20Tech%20Ed...
Submission: On March 01 via api from US — Scanned from DE

Form analysis 2 forms found in the DOM

GET /search

<form method="GET" action="/search" class="flex items-center justify-between w-full"><input type="text" name="searchTerm" placeholder="SEARCH" class="bg-white p-1 rounded-md border-0 w-[80%] text-black" required=""><input type="submit" value="SEARCH"
    class="ml-2 cursor-pointer bg-search-box-button-bg text-search-box-button-text hover:bg-search-box-button-hover-bg hover:text-search-box-button-hover-text ronded rounded-md p-1 font-bold w-[20%]"></form>

GET /search

<form method="GET" action="/search" class="flex items-center justify-between w-full"><input type="text" name="searchTerm" placeholder="SEARCH" class="bg-white p-1 rounded-md border-0 w-[80%] text-black" required=""><input type="submit" value="SEARCH"
    class="ml-2 bg-search-box-button-bg text-search-box-button-text ronded rounded-md p-1 font-bold w-[20%]"></form>

Text Content

News
Latest News
FDA News
Adverse Event Management
Supportive Care
Disparities in Cancer Care
Drug Safety
Radiation Oncology
Survivorship
Practice Management
Prevention
Contributors
Media
Expert Connections
Podcasts
Videos
Conferences
Conference Coverage
Conference Listing
Publications
CME/CE
Continuing Education
Resources
Case-Based Digest
Oncology Drug Crash Course
Webinars
Cancer Summary Slides
MPN Symptom Management
Subscribe
Print Subscription
eNewsletter
Partners



Specialty
Advanced Practice Providers
Clinical
Breast CancerGastrointestinal CancerGenitourinary CancerGynecologic
CancerHematologyImmunotherapyLung CancerMyeloproliferative NeoplasmsNurse
NavigationPreventionSupportive Care
Quality Improvement
News
Latest News
FDA News
Adverse Event Management
Supportive Care
Disparities in Cancer Care
Drug Safety
Radiation Oncology
Survivorship
Practice Management
Prevention
Contributors
Media
Expert Connections
Podcasts
Videos
Conferences
Conference Coverage
Conference Listing
Publications
CME/CE
Continuing Education
Resources
Case-Based Digest
Oncology Drug Crash Course
Webinars
Cancer Summary Slides
MPN Symptom Management
Subscribe
Print Subscription
eNewsletter
Partners

Advertisement

Breast Cancer

| Lung Cancer

| Gynecologic Cancers

| Hematology

| Skin Cancer

| Supportive Care

| Adverse Event Management

| Brain Cancer

| Disparities in Cancer Care

| Drug Safety

| Gastrointestinal Cancer

| Genetics

| Genitourinary Cancer

| Head and Neck Cancers

| Immuno-Oncology

| Myeloproliferative Neoplasms

| Nurse Navigation

| Pediatric Cancer

| Practice Management

| Prevention

| Radiation Oncology

| Sarcomas

| Survivorship

View All >>
 * Adverse Event Management
 * Brain Cancer
 * Breast Cancer
 * Disparities in Cancer Care
 * Drug Safety
 * Gastrointestinal Cancer
 * Genetics
 * Genitourinary Cancer
 * Gynecologic Cancers
 * Head and Neck Cancers
 * Hematology
 * Immuno-Oncology
 * Lung Cancer
 * Myeloproliferative Neoplasms
 * Nurse Navigation
 * Pediatric Cancer
 * Practice Management
 * Prevention
 * Radiation Oncology
 * Sarcomas
 * Skin Cancer
 * Supportive Care
 * Survivorship


PRIOR AUTHORIZATION IS TOP ADMINISTRATIVE CHALLENGE OF 2023

February 16, 2023
Feature
Article
Oncology Nursing NewsFebruary 2023
Volume 17
Issue 1



Prior authorization costs clinicians time and money. Heading into 2023, prior
authorization was listed as a top administrative challenge.

Prior Authorization Is Top Administrative Challenge of 2023



The number of prior authorization requests continues to increase despite
promises to the contrary by payers. The increase is costing physicians time and
money. In a Medical Group Management Association (MGMA) poll, 70% of medical
groups queried indicated that prior authorizations had increased in the past
year.

Physicians say their practices continue to struggle with either a lack of
response or no response from payers, increased time spent by staff to try to
gain approval, and a lack of automation in the process.

These difficulties can lead to delays in patient care. A University of Colorado
study found that 93% of physicians reported care delays and that 82% reported
cases of treatment abandonment (when the patient does not follow through)
because of prior authorization requirements.

“There’s not 1 standardized way to submit prior authorizations or additional
information— maybe clinical information or chart information—to the health
plans,” Anders M. Gilberg, MGA, senior vice president of government affairs for
MGMA, said. “Each health plan thinks they have the best proprietary way to make
it really easy.”

But for practices with 20 to 30 payers, that can mean 20 to 30 different
websites and passwords.

“The way it works is you have to hire staff to go in there and learn each of
those processes, which is time consuming and redundant,” Gilberg said. “Ideally,
we’re looking for 1 standard and 1 way of submitting them, such as pushing a
button or maybe having it integrated with an electronic medical record and the
clinical record. We could provide the information health plans need but [we want
to] do so in a streamlined way….”

Although that solution doesn’t exist yet and physicians can’t change the prior
authorization demands from payers, they can take the following steps to minimize
the burden.

Designate a prior authorization champion.

Having 1 staff member run point on prior authorizations will help that
individual learn what each payer wants and the best ways to get authorizations
approved in a timely manner.

Keep detailed notes for each patient.

All it takes is 1 piece of information to be missing from a patient’s chart for
a payer to deny the authorization. Always keep this in mind when documenting a
patient’s condition and what tests have been done. If something is abnormal,
document it.

Learn what payers want.

Payers will have different requirements before authorizing tests such as an MRI.
If the payer requires an x-ray first, make a note of that for future reference
and complete as many of the requirements as possible before submitting the prior
authorization.

Be persistent.

Just because a payer denies the first request doesn’t mean you should give up.
Some payers have staff with minimal medical backgrounds who review initial
requests and may just be looking for key trigger words as a reason to reject a
claim. An appeal will most likely go to someone with more medical training.

Recruit the patient.

Have the patient call the insurance company if necessary. They will be talking
to a different department and may either get a different answer or gain clues as
to what is needed to get the prior authorization approved.

Escalate, escalate, escalate.

There is little point in arguing with a payer-employed nurse over a complex
medical issue that may be well outside their expertise. Ask for a peer-to-peer
review or, in extreme cases, to speak with the medical director or chief medical
officer. They still may not have experience in the relevant specialty but will
at least have a background to better understand the specific challenge being
addressed.

Download Issue PDF
Articles in this issue

--------------------------------------------------------------------------------

A Plea to Let Patients With Cancer “Just Eat”

Prior Authorization Is Top Administrative Challenge of 2023

Nursing Education Can Be a Lifelong Marathon. Are You Ready for the Race?

Considerations for Premenopausal Women With TNBC

Updates in Triple-Negative Breast Cancer Treatment

Preparing Patients for CAR T-Cell Therapy With Confidence

Futibatinib Approval Ushers in Targeted Therapy Option for Patients With
Unresectable, Intrahepatic FGFR2-Positive Cholangiocarcinoma

Related Videos
Key Takeaways for Patients With Myelofibrosis

Dosing JAK Inhibitors in Patients With Myelofibrosis

Best Approaches to Switching Therapies for a Patient With Myelofibrosis

Assessing Treatment Response in Patients With Myelofibrosis

Adverse Events Seen With JAK Inhibitors for Myelofibrosis

Clinical Data on the Approved JAK Inhibitors for Treatment of Myelofibrosis

Management of Anemia in Patients With Myelofibrosis

Key Patient Goals for Myelofibrosis Management

Educational Resources for Patients Diagnosed With Myelofibrosis

Assessing Risk Level of Patients With Myelofibrosis

Related Content


Advertisement


--------------------------------------------------------------------------------

Perioperative Tislelizumab Plus Chemo Improves Event-Free Survival in Resectable
NSCLC


March 1st 2024
Article



Treatment with neoadjuvant tislelizumab plus platinum-based doublet
chemotherapy, followed by surgery and adjuvant tislelizumab, improved event-free
survival in patients with resectable non–small cell lung cancer.




--------------------------------------------------------------------------------

What New Cancer Drugs Were Approved in 2023?


January 1st 2024
Podcast



In this special episode of The Vitals, we ring in the New Year 2024 by combing
through 2023 FDA approvals.




--------------------------------------------------------------------------------



Immune Engager Therapies Improve Responses, PFS in RRMM After CAR T-Cell Therapy


February 29th 2024
Article



Immune engager therapies, according to a retrospective study of real-world
patients, had the best rates of responses and progression-free survival in
patients with multiple myeloma whose disease relapsed after treatment with
idecabtagene vicleucel.




--------------------------------------------------------------------------------

Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies


December 14th 2023
Podcast



Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the
2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.




--------------------------------------------------------------------------------

Long-Term Survivors of Childhood Cancer at Higher Risk of Death Following Heart
Issues; Threshold for Treating Risk Factors Should Be Lower


February 28th 2024
Article



New research out of VCU Massey Comprehensive Cancer Center and VCU Health Pauley
Heart Center indicates that survivors of childhood cancer are at a significantly
higher risk of death following a major cardiovascular event — including heart
failure, heart attack or stroke — than the general public.




--------------------------------------------------------------------------------

Mindfulness as Self-Care in Oncology Nursing May Also Improve Patient Care


February 28th 2024
Article



An expert discussed how the benefits of mindfulness in patients with cancer can
also be applied to oncology nurses.



Related Content


Advertisement


--------------------------------------------------------------------------------

Perioperative Tislelizumab Plus Chemo Improves Event-Free Survival in Resectable
NSCLC


March 1st 2024
Article



Treatment with neoadjuvant tislelizumab plus platinum-based doublet
chemotherapy, followed by surgery and adjuvant tislelizumab, improved event-free
survival in patients with resectable non–small cell lung cancer.




--------------------------------------------------------------------------------

What New Cancer Drugs Were Approved in 2023?


January 1st 2024
Podcast



In this special episode of The Vitals, we ring in the New Year 2024 by combing
through 2023 FDA approvals.




--------------------------------------------------------------------------------



Immune Engager Therapies Improve Responses, PFS in RRMM After CAR T-Cell Therapy


February 29th 2024
Article



Immune engager therapies, according to a retrospective study of real-world
patients, had the best rates of responses and progression-free survival in
patients with multiple myeloma whose disease relapsed after treatment with
idecabtagene vicleucel.




--------------------------------------------------------------------------------

Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies


December 14th 2023
Podcast



Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the
2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.




--------------------------------------------------------------------------------

Long-Term Survivors of Childhood Cancer at Higher Risk of Death Following Heart
Issues; Threshold for Treating Risk Factors Should Be Lower


February 28th 2024
Article



New research out of VCU Massey Comprehensive Cancer Center and VCU Health Pauley
Heart Center indicates that survivors of childhood cancer are at a significantly
higher risk of death following a major cardiovascular event — including heart
failure, heart attack or stroke — than the general public.




--------------------------------------------------------------------------------

Mindfulness as Self-Care in Oncology Nursing May Also Improve Patient Care


February 28th 2024
Article



An expert discussed how the benefits of mindfulness in patients with cancer can
also be applied to oncology nurses.




Advertisement



LATEST CONFERENCE COVERAGE

Immune Engager Therapies Improve Responses, PFS in RRMM After CAR T-Cell Therapy



Liso-Cel Elicits Rapid, Durable Responses in Relapsed/Refractory CLL/SLL



Adding Azoles May Not Impact Efficacy of Ruxolitinib in Acute GVHD Treatment



Ruxolitinib Plus Belumosudil Confers a 55% Response Rate in GVHD

View More Latest Conference Coverage
Advertisement

Recent Content

Perioperative Tislelizumab Plus Chemo Improves Event-Free Survival in Resectable
NSCLC



We Advance, Together



Immune Engager Therapies Improve Responses, PFS in RRMM After CAR T-Cell Therapy



Label Expansion for Oral Ibrutinib Suspension Gets FDA Approval

View More Recent Content
Advertisement

x

CancerNetwork.com
CureToday.com
OncLive.com
TargetedOnc.com
Advertise
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777



© 2024 MJH Life Sciences

All rights reserved.